bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.
Gehan Xu, Liang Cui, Jin Li, Quanren Wang, Pansong Li, Xuefeng Xia, Xin Yi, Quanlin Guan, Jianming Xu
Author Information
- Gehan Xu: The First Clinical Medical College of Lanzhou University, Lanzhou, China.
- Liang Cui: Geneplus-Beijing Institute, Beijing, China. ORCID
- Jin Li: Geneplus-Beijing Institute, Beijing, China.
- Quanren Wang: Jiangsu Hengrui Medicine Co. Ltd., Jiangsu, China.
- Pansong Li: Geneplus-Beijing Institute, Beijing, China. ORCID
- Xuefeng Xia: Geneplus-Beijing Institute, Beijing, China.
- Xin Yi: Geneplus-Beijing Institute, Beijing, China.
- Quanlin Guan: Department of Oncology Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
- Jianming Xu: Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. ORCID
No abstract text available.
- Ann Oncol. 2021 May;32(5):661-672
[PMID: 33736924]
- Int J Cancer. 2021 Apr 5;:
[PMID: 33818764]
- Genomics Proteomics Bioinformatics. 2017 Feb;15(1):14-18
[PMID: 28387199]
- J Clin Oncol. 2020 Sep 10;38(26):2960-2970
[PMID: 32716739]
- J Hematol Oncol. 2018 Nov 6;11(1):129
[PMID: 30400986]
- Nucleic Acids Res. 2020 Jan 8;48(D1):D24-D33
[PMID: 31702008]
- Clin Cancer Res. 2021 Feb 15;27(4):1003-1011
[PMID: 33087333]
- Nat Med. 2022 Aug;28(8):1599-1611
[PMID: 35739268]
- Front Immunol. 2021 Feb 01;11:629722
[PMID: 33597954]
- Lancet Oncol. 2018 Jul;19(7):940-952
[PMID: 29875066]
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Carcinoma, Hepatocellular
Humans
Immune Checkpoint Inhibitors
Liver Neoplasms
Prognosis
Pyridines
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Pyridines
apatinib
camrelizumab
